ReviewThe American journal of the medical sciences2026
Update on Influenza.
Review in The American journal of the medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of baloxavir marboxil vs. oseltamivir in Chinese outpatients with influenza B: an IPTW-adjusted real-world cohort study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Observational
- Pixavir Marboxil: First Approval.Drugs · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Influenza continues to challenge global health systems due to its evolving clinical and epidemiological features, with significant morbidity and mortality worldwide. Vaccine development remains a cornerstone of prevention, with attention to annual strain selection and enhanced formulations such as adjuvanted, high-dose, and recombinant vaccines. Promising innovations on the horizon include next-generation influenza vaccines, multi-pathogen vaccines, and universal influenza vaccines, with new technologies employing mRNA platforms and alternative vaccine administration strategies. The role of antivirals for prophylaxis and treatment are evaluated, including synergistic effects and resistance trends. Considerations for vulnerable populations with increased risk are highlighted. This review provides a timely synthesis of current knowledge and emerging strategies in diagnostics, therapeutics, and prevention to strengthen clinical outcomes and public health responses to influenza in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.